(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

M Nomura; S Kinoshita; H Satoh; T Maeda; K Murakami; M Tsunoda; H Miyachi; K Awano

doi:10.1016/s0960-894x(99)00039-6

(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents

Bioorg Med Chem Lett. 1999 Feb 22;9(4):533-8. doi: 10.1016/s0960-894x(99)00039-6.

Authors

M Nomura¹, S Kinoshita, H Satoh, T Maeda, K Murakami, M Tsunoda, H Miyachi, K Awano

Affiliation

¹ Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan.

PMID: 10098657
DOI: 10.1016/s0960-894x(99)00039-6

Abstract

A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure-activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluorome thyl)-phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus.

MeSH terms

Animals
Blood Glucose / analysis
Hypoglycemic Agents / chemistry*
Hypoglycemic Agents / pharmacology*
Insulin / blood
Mice
Mice, Obese
Pioglitazone
Structure-Activity Relationship
Thiazoles / chemistry*
Thiazoles / pharmacology*
Thiazolidinediones*
Thiazolidines
Triglycerides / blood

Substances

Blood Glucose
Hypoglycemic Agents
Insulin
Thiazoles
Thiazolidinediones
Thiazolidines
Triglycerides
5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide
Pioglitazone